An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
NCT ID: NCT02612935
Last Updated: 2017-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
88 participants
OBSERVATIONAL
2015-03-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
NCT06283524
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853
Digital Cognition in Multiple Sclerosis
NCT03569618
CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis
NCT05671055
Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study
NCT03335618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Upon creating an account, users would be asked to complete a short demographic survey (Information About You, which includes age, sex, race/ethnicity, education, occupation) and two additional short surveys: a Computer Experience Questionnaire and a Perceptions of Brain Training questionnaire. In addition, participants will be assessed with the Montreal Cognitive Assessment (MOCA), and be directed to take the Brain Performance Test (on a laptop or desktop computer) within the first 7 days of creating their account. If not conducted within the previous 3 months, participants would also be required to have the following assessments at baseline (i.e., within the first 7 days): Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), Multiple Sclerosis Impact Scale-29 (MSIS-29), and Beck Depression Inventory (BDI). After one week of using Lumosity, and then every other month for 12 months, participants would be asked to complete a short questionnaire about their experience with Lumosity. Every 3 months, participants would repeat the BPT, MSNQ, and BDI; and every 6 months, they would repeat the MSIS. Finally, at the end of the study, the end of the study they would also repeat the MOCA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lumosity
Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed informed consent
2. 18 years of age or older,
3. English-speaking,
4. Current participants in the MS Achievement Center Cognitive Wellness Program
5. Sufficient physical capacity to use a computer keyboard and mouse
6. Willing and able to use Lumosity at least 3 times per week
Exclusion Criteria
1. Under 18 years of age
2. Are taking medication that may impede cognitive functioning
3. Have other conditions or problems that may preclude regular computer usage
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dignity Health
OTHER
Lumos Labs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Hutchinson
Role: PRINCIPAL_INVESTIGATOR
MS Achievement Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LL009 - MS ACHIEVEMENT STUDY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.